ArticleFrontiers in immunology2017
The Transcription Factor ZNF683/HOBIT Regulates Human NK-Cell Development.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Effects of Daily Raspberry Consumption on Immune-Metabolic Health in Subjects at Risk of Metabolic Syndrome: A Randomized Controlled Trial.Nutrients · 2020Trial
- Transcriptional networks weaving natural killer anti-tumor immune response.Molecular cancer · 2026Review
- Rewiring tumor immunity via zinc finger proteins: a new frontier in cancer immunotherapy.Journal of translational medicine · 2025Review
- Genome Variation in Alcohol Use Disorder by Whole-Exome Sequencing.Addiction biology · 2025Article
- Multi-omics analysis of zinc finger protein 683 as a prognostic biomarker for immune infiltration in clear cell renal cell carcinoma.BMC cancer · 2025Article
- Natural killer cells in skin: a unique opportunity to better characterize the many facets of an overlooked secondary lymphoid organ.Frontiers in immunology · 2025Review
- Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies.Frontiers in immunology · 2025Review
- Article
- The Use of Machine Learning in the Diagnosis of Kidney Allograft Rejection: Current Knowledge and Applications.Diagnostics (Basel, Switzerland) · 2024Review
- CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.Nature communications · 2024Article
- Proteomics and transcriptomics combined reveal specific immunological markers in autoimmune thyroid disease.Frontiers in immunology · 2024Article
- Transcriptomics profiling of the non-small cell lung cancer microenvironment across disease stages reveals dual immune cell-type behaviors.Frontiers in immunology · 2024Article
- CD56Frontiers in immunology · 2024Article
- Identification ofFrontiers in oncology · 2023Article
- Single-Cell Profiling of the Immune Atlas of Tumor-Infiltrating Lymphocytes in Endometrial Carcinoma.Cancers · 2022Article
- The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma.Gut · 2022Article
- BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells.Oncoimmunology · 2022Article
- Development of Human ILCs and Impact of Unconventional Cytotoxic Subsets in the Pathophysiology of Inflammatory Diseases and Cancer.Frontiers in immunology · 2022Review
- Characteristic Genes and Immune Infiltration Analysis for Acute Rejection after Kidney Transplantation.Disease markers · 2022Article
- IRF2 is required for development and functional maturation of human NK cells.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
We identified
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.